Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Black box economics: Russia’s internal struggle over classified financial data
    • Scholz rules out sending fighter jets to Ukraine
    • Drones target Iranian military site in Isfahan
    • EU to consider listing Iran’s Revolutionary Guards as terrorists
    • China targets consumption in bid to drive growth
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Adani Group says short seller’s report was ‘calculated attack on India’
      • Rio Tinto apologises for losing highly radioactive capsule
      • EY came close to uncovering Wirecard fraud in 2016
      • Adani Group shares and bonds extend sell-off
      • Has Illumina taken the wrong path in its Grail quest?
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Central banks set to lift interest rates to 15-year highs as investor jitters grow
      • Live news: UK opposition demands Sunak reveal what he knew of Zahawi’s tax affairs
      • ‘Flying with one engine’: why global food supplies are at risk despite falling crop prices
      • Commodity trade costs surge as industry seeks up to $500bn in extra finance
      • BP cuts long-term forecast for oil and gas demand
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The world is not ready for the long grind to come
      • The shock of mass lay-offs is only the beginning for companies
      • Beware hollowing out the City of London
      • Zahawi affair raises doubts over Sunak’s ruthlessness
      • The grim world of office spyware
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
      • A new generation refuses to keep quiet on age discrimination at work
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Russian radio host Alexei Venediktov: ‘We didn’t hear the sound of army boots marching’
      • India against Gandhi — a legacy rewritten
      • Why I’m only buying five new things in 2023
      • How London’s property market became an inheritocracy
      • Four cultural spots to hit this spring
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Purdue Pharma LP

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 27 April, 2022
      Pharmaceuticals sector
      McKinsey rebuts conflict claims over work for health regulator and opioid makers

      Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade

    • Thursday, 3 March, 2022
      Purdue and US states agree new $6bn settlement for opioid litigation

      Members of Sackler family who owned OxyContin maker will increase financial contribution but still receive a legal shield

    • Friday, 18 February, 2022
      US opioid epidemic
      Sackler owners offer up to $6bn to settle Purdue Pharma bankruptcy

      Proposal revealed by court mediator comes after a judge rejected earlier deal

    • Friday, 17 December, 2021
      Lex
      Sacklers/opioids: upended bankruptcy will be good for lawyers and perhaps no one else Premium content

      It is unfortunate that critics of the current system have not articulated a better one for the aggrieved

    • Friday, 17 December, 2021
      US opioid epidemic
      Judge overturns $4.5bn opioid-related settlement in Purdue Pharma bankruptcy

      Sackler family was to make multibillion-dollar contribution in exchange for protection from lawsuits

    • Thursday, 9 December, 2021
      US opioid epidemic
      Sackler name to be removed from Metropolitan Museum of Art galleries

      Move is the latest fallout for members of the family that owned opioid maker Purdue Pharma

    • Thursday, 4 November, 2021
      InterviewTelevision
      ‘We’ve been screaming’: the makers of Dopesick on reframing the opioid crisis

      Writer Beth Macy and director Barry Levinson discuss taking on the Sacklers and victim-blaming in their mini-series

    • Wednesday, 1 September, 2021
      Sacklers shielded from future lawsuits in Purdue settlement

      Judge approves bankruptcy plan for opioid maker in which family will pay $4.5bn

    • Sunday, 8 August, 2021
      News in-depthUS opioid epidemic
      Purdue’s bankruptcy deal shields Sackler family owners from future opioid liability

      Critics say concessions in case regarding the company diminishes accountability in overdose scandal

    • Thursday, 8 July, 2021
      US opioid epidemic
      Purdue secures backing from more states for settlement

      Agreement with holdouts brings US drugmaker a step closer to emerging from bankruptcy

    • Wednesday, 28 April, 2021
      ReviewFT Books Essay
      Empire of Pain — the story of the Sacklers and OxyContin

      Patrick Radden Keefe’s saga of how a pharmaceutical dynasty unleashed a wave of dependency and grew rich from it

    • Monday, 22 March, 2021
      McKinsey
      McKinsey reaches $45m opioid settlement with Nevada

      Agreement brings consultancy’s total bill for prescription painkiller advice to $619m

    • Tuesday, 16 March, 2021
      US opioid epidemic
      Sackler family offers to pay $4.3bn in bankruptcy settlement

      Owners of opioid maker Purdue Pharma pledge extra money to win over US states that rejected deal

    • Tuesday, 16 February, 2021
      Due Diligence
      A closer look at McKinsey’s mysterious firings Premium content

      Answers emerge as to the unexplained departures from the consultancy’s investment banking research unit

    • Monday, 15 February, 2021
      Tom Peters
      McKinsey’s work on opioid sales represents a new low

      My former consultancy demonstrates what is wrong with business school graduates

    • Friday, 5 February, 2021
      Due Diligence
      McKinsey’s most pressing client: itself Premium content

      After settling opioid crisis-related claims and separately firing two partners, the consultancy weighs its next move

    • Friday, 29 January, 2021
      US opioid epidemic
      McKinsey in advanced talks with US states to settle opioid claims

      Consultancy not likely to admit wrongdoing or liability over its advising of drug companies

    • Thursday, 17 December, 2020
      US opioid epidemic
      Members of Sackler family refuse to take blame for US opioid crisis

      Two former board members tell Congress they do not bear personal responsibility for addiction epidemic

    • Sunday, 25 October, 2020
      The FT ViewThe editorial board
      Securing justice for the victims of opioid abuse

      Investigators must bring to book the highest profile perpetrators

    • Thursday, 22 October, 2020
      Lex
      Purdue/Goldman: tough penalties are well-judged Premium content

      Punitive actions do not just exact narrow justice — they serve as a deterrent against future misdeeds

    • Wednesday, 21 October, 2020
      US opioid epidemic
      Opioid maker Purdue Pharma agrees $8bn US settlement

      Members of billionaire Sackler family to pay $225m in related civil settlement

    • Tuesday, 17 December, 2019
      US opioid epidemic
      Sacklers withdrew over $10bn from Purdue during decade opioid crisis erupted

      Some states have targeted family members in opioid lawsuits after company bankruptcy

    • Monday, 16 September, 2019
      Purdue Pharma files for bankruptcy as some states stall on opioid deal

      Opiod maker owned by Sackler family has yet to reach deal with all attorneys-general

    • Thursday, 12 September, 2019
      FT News Briefing podcast9 min listen
      Opioid deal, Yellowhammer document, HK bid for LSE

      Purdue Pharma strikes a preliminary deal with US states over opioid crisis claims

    • Wednesday, 11 September, 2019
      Purdue reaches preliminary opioid deal with several states

      New York, Pennsylvania and Washington among those to rebuff settlement

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In